$1.54
2.66%
(+0.04)
Previous close $1.51
NICI Rating

Latest Updates on CRBP

Loading Chart...

Latest Trading on NASDAQ

$1.54
2.66%
(+0.04)
Open 1.45
Previous Close 1.51
Today's Range
1.39 1.56
52 Week Range
1.39 9.78
Volume 3.40M
Avg. Volume (Weekly) 10.62M
Bid 1.54
Ask 1.55
Market Cap 122.98K
EPS -1.68
Shares Outstanding 81.71K
YTD High 9.78
Updated November 27, 2018

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals is a pharmaceutical company working on therapies for inflammatory and fibrotic diseases. They are in the clinical stage of drug development for a subset of drugs that interact with the endocannabinoid system – the system in our bodies that responds to compounds in cannabis like THC and CBD.

No data to display.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.